Business Wire

Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023

Share

Incyte (Nasdaq:INCY) today announced that abstracts featuring new data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid.

"We look forward to sharing data from our oncology portfolio with the scientific community at this year’s ESMO Congress,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “Presentations, including results from studies of retifanlimab and capmatinib, focused on patients with endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer, showcase our continued efforts to pursue innovative therapies for patients with cancer.”

Key abstracts from Incyte-sponsored and partner programs include:

Poster Presentations

Immuno-oncology (IO)

Retifanlimab in Patients with Recurrent Microsatellite Instability-High (MSI-H) or Deficient Mismatch Repair (dMMR) Endometrial Cancer: Final Results from the POD1UM-101 Study (Cohort H) (Abstract #755P. Topic: Gynecological Cancers. Sunday, October 22, 6:00 a.m. – 7:00 a.m. ET)

Updated Results from POD1UM-201: A Phase 2 Study of Retifanlimab in Patients with Advanced or Metastatic Merkel Cell Carcinoma (MCC) (Abstract #1146P. Topic: Melanoma and Other Skin Tumors. Sunday, October 22, 6:00 a.m. – 7:00 a.m. ET)

Capmatinib

Efficacy of Capmatinib Compared to Standard of Care for German Patients with Locally Advanced or Metastatic NSCLC Harboring METex14 Mutations: Results from the RECAP Study1(Abstract #1383P. Topic: NSCLC, Metastatic. Monday, October 23, 6:00 a.m. – 7:00 a.m. ET)

Capmatinib vs Docetaxel as Second- or Third-line (2/3L) Therapy in Patients (Pts) with METex14-Mutated Advanced NSCLC (aNSCLC): The GeoMETry-3 Trial1(Abstract #1391P. Topic: NSCLC, Metastatic. Monday, October 23, 6:00 a.m. – 7:00 a.m. ET)

For full session details and data presentation listings, please see the ESMO Congress 2023 (https://www.esmo.org/meeting-calendar/esmo-congress-2023/programme) online program.

About Zynyz™ (retifanlimab-dlwr)

Zynyz (retifanlimab-dlwr), is an intravenous PD-1 inhibitor indicated in the U.S. for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Zynyz is marketed by Incyte in the U.S. In 2017, Incyte entered into an exclusive collaboration and license agreement with MacroGenics, Inc. for global rights to retifanlimab.

Zynyz is a trademark of Incyte.

About Tabrecta® (capmatinib)

Tabrecta is approved in several countries including the EU, United States (U.S.), Japan and Switzerland. It is the number one prescribed targeted therapy for patients with advanced non-small cell lung cancer (NSCLC) with alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping globally2.

Tabrecta is a kinase inhibitor that targets mesenchymal-epithelial transition (MET). Tabrecta was discovered by Incyte and licensed to Novartis in 2009. Under the agreement, Incyte granted Novartis worldwide exclusive development and commercialization rights to capmatinib and certain back-up compounds in all indications.

About Incyte

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline, whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions and Incyte’s goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA, and other regulatory authorities; the efficacy or safety of Incyte and its partners’ products; the acceptance of Incyte and its partners’ products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended June 30, 2023. Incyte disclaims any intent or obligation to update these forward-looking statements.

______________________________
1 Novartis-sponsored abstract
2 Data on file 

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
media@incyte.com

Investors
ir@incyte.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BlueConic Named the Only Challenger in Inaugural 2024 Gartner® Magic Quadrant™ for Customer Data Platforms21.2.2024 18:33:00 CET | Press release

Market-leading customer data platform (CDP) BlueConic today announced that it has been recognized as the only Challenger in the inaugural Magic Quadrant for Customer Data Platforms. We believe this industry recognition marks a major milestone for CDPs and the maturity of the space on a global scale. BlueConic differentiates from other vendors for its: Privacy-by-design philosophy: Maintaining responsible data practices is essential for garnering consumer trust, but maintaining compliance with a patchwork of regulations is only getting more difficult. That’s why BlueConic has been built with privacy at the forefront. The platform has been purposely designed to collect first-party data in ways that ensures it is unified, actionable, and privacy-compliant. Collecting and using data within the framework of privacy regulations like GDPR and CCPA enables companies to build trust and deliver valuable customer experiences, while mitigating their consumer data risk at the same time. Easy-to-use

Bynder named a “Leader” in Digital Asset Management by independent research firm21.2.2024 17:58:00 CET | Press release

Bynder, the global, enterprise digital asset management (DAM) platform, has been named a “Leader” in The Forrester Wave™: Digital Asset Management Systems, Q1 2024 report by Forrester Research, Inc. Bynder received a top score in the revenue category, with the report stating that “Bynder invests to play a transformative role in the digital-first economy.” In the past two years since the last report was launched, Bynder has surpassed $130m in ARR, announced a majority investment from Thomas H. Lee Partners, made two acquisitions, developed its enterprise partner ecosystem, launched more than 45 out of the box integrations and expanded its suite of product offerings to include AI capabilities and other new innovations that are redefining DAM. According to a quote from a customer reference in the report “the AI search and smart filter system in Bynder simplifies the process of finding the exact assets you’re looking for.” These recent AI innovations have highlighted the company’s market l

Parse Biosciences Launches Evercode Whole Transcriptome Version 3, Boosting Usability and Performance21.2.2024 17:00:00 CET | Press release

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced a significant update to the company’s flagship Evercode™ Whole Transcriptome products. Available to ship in mid-March, Evercode Whole Transcriptome version 3 kits offer researchers a more streamlined workflow, more flexible and higher throughput fixation, and optimized reagents for improved sensitivity in gene detection. With the new version, customers will enjoy a more streamlined and flexible workflow, helping them move from samples to results more quickly. These enhancements are delivered while significantly improving upon the previous version’s sensitivity and library complexity, giving researchers higher biological resolution and insight into their samples. Parse customers already rely on the utility of Evercode fixation, which enables them to fix cells or nuclei when they become available, store them for up to six months, and then sequence them when ready. Fixation i

Tigo Energy Expands Comprehensive Residential Energy Solution for Italy with GO EV Charger21.2.2024 15:00:00 CET | Press release

Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced the launch of the GO EV Charger for the Italian market. A smart residential electric vehicle (EV) charging station, GO EV Charger offers solar installers a way to add e-mobility that seamlessly integrates with the Tigo EI (Energy Intelligence) Residential Solar Solution, which includes inverter, battery system, TS4 MLPE devices, and everything else required for fast, flexible, and dependable solar installations. The Tigo EI Residential Solar Solution will be on display from February 28th to March 1st at KEY - The Energy Transition Expo in Rimini, Italy. Previously released for the German market, the GO EV Charger features seamless integration with the Tigo EI Residential solar-plus-storage solution. The GO EV Charger is available in single- or three-phase variants, up to 22 kW, and delivers high flexibility with multiple charging modes, current limits, and scheduling

Talkdesk Hires Software Veteran Albert Caravelli to Lead, Grow Strategic Alliances and Partners21.2.2024 15:00:00 CET | Press release

Talkdesk®, Inc., a global AI-powered contact center leader for enterprises of all sizes, today announced that Albert (Al) Caravelli, an accomplished executive experienced in transforming sales and alliances organizations at some of the world’s leading software companies, has joined the company as senior vice president of Alliances and Partners. In this role, Caravelli is responsible for expanding and nurturing Talkdesk’s growing ecosystem of strategic technology alliance partners, global system integrators, and global service providers. Caravelli comes to Talkdesk following nearly nine years at cloud security company Zscaler, where he most recently served as global vice president of strategic alliances and advisory firms, responsible for leading Zscaler’s go-to-market strategy and execution. During this time, he was instrumental in the formation of strategic alliances with multiple companies, including Accenture, Capgemini, Deloitte, HCL, Infosys, AT&T, BT, Cognizant, Deutsche Telekom,

HiddenA line styled icon from Orion Icon Library.Eye